Recalls from Hikma Pharmaceuticals USA INC.

• Hikma Abirtega (Abiraterone Acetate) Tablets (opens in a new tab)
  Moderate risk, FDA, Oct 16, 2026, Quality testing problem
• Exelan Pharmaceuticals Ramipril Capsules USP (opens in a new tab)
  Moderate risk, FDA, Aug 26, 2026, Drug impurity
• Hikma Pharmaceuticals Alendronate Sodium Oral Solution (opens in a new tab)
  Moderate risk, FDA, Apr 29, 2026, Quality testing problem

Data: Recall Canary (opens in a new tab)